nach oben

Community Mental Health Journal

Erschienen in:

06.11.2023 | Original Paper

The Intersectional Impact of Cost-Related Non-Adherence and Depression: A Cross-Sectional Analysis of the Canadian Community Health Survey by Sex, Race, and Indigeneity

verfasst von: Nevena Rebić, Michael R. Law, Lori A. Brotto, Jacquelyn J. Cragg, Mary A. De Vera

Erschienen in: Community Mental Health Journal | Ausgabe 3/2024

Einloggen, um Zugang zu erhalten

Abstract

We evaluated the relationship between cost-related non-adherence (CRNA) and depressive symptoms. Pooling data from the 2015, 2016, 2018, and 2019 annual Canadian Community Health Survey, we analyzed the relationship between CRNA and moderate to severe depressive symptoms, assessed by the Patient Health Questionnaire (PHQ-9). Among the sample, 4.9% experienced CRNA and 6.8% experienced moderate to severe depressive symptoms. Respondents who reported CRNA had 1.51 (95% confidence interval [CI], 1.51–1.52) greater odds of experiencing moderate to severe depressive symptoms. Stratified analysis by sex and race showed the association between CRNA and depressive symptoms was greatest among racialized males (aOR: 1.83, 95% CI: 1.81– 1.85). Stratified analysis by sex and Indigeneity showed this association was greatest for Indigenous males (aOR: 2.16, 95% CI: 2.10–2.22). Forgoing prescribed medications due to cost is associated with more severe depressive symptoms among Canadians, particularly racialized and Indigenous males.

Nur mit Berechtigung zugänglich

Akhtar-Danesh, N., & Landeen, J. (2007). Relation between depression and sociodemographic factors. Int J Ment Health Syst, 1(1), 4. https://doi.org/10.1186/1752-4458-1-4CrossRefPubMedPubMedCentral

Alefan, Q., Cheekireddy, V. M., & Blackburn, D. (2022). Cost-related nonadherence can be explained by a general nonadherence framework. Journal of the American Pharmacists Association, 62(3), 658–673. https://doi.org/10.1016/j.japh.2022.01.011CrossRefPubMed

Bailey, R. K., Mokonogho, J., & Kumar, A. (2019). Racial and ethnic differences in depression: Current perspectives. Neuropsychiatric Disease and Treatment, 15, 603–609. https://doi.org/10.2147/NDT.S128584CrossRefPubMedPubMedCentral

Daw, J. R., & Morgan, S. G. (2012). Stitching the gaps in the Canadian public drug coverage patchwork? A review of provincial pharmacare policy changes from 2000 to 2010. Health Policy, 104(1), 19–26. https://doi.org/10.1016/j.healthpol.2011.08.015CrossRefPubMed

Demers, V., Melo, M., Jackevicius, C., Cox, J., Kalavrouziotis, D., Rinfret, S., & Pilote, L. (2008). Comparison of provincial prescription drug plans and the impact on patients’ annual drug expenditures. Cmaj, 178(4), 405–409. https://doi.org/10.1503/cmaj.070587CrossRefPubMedPubMedCentral

Dewa, C. S., Hoch, J. S., & Steele, L. (2005). Prescription drug benefits and Canada’s uninsured. International Journal of Law and Psychiatry, 28(5), 496–513. https://doi.org/10.1016/j.ijlp.2005.08.003CrossRefPubMed

Diagnostic and statistical manual of mental disorders: DSM-5. (2013). Arlington, VA: American Psychiatric Association.

Fuller-Thomson, E., Lee, S., Cameron, R. E., Baiden, P., Agbeyaka, S., & Karamally, T. M. (2020). Aboriginal peoples in complete mental health: A nationally-representative Canadian portrait of resilience and flourishing. Transcultural Psychiatry, 57(2), 250–262. https://doi.org/10.1177/1363461519885702CrossRefPubMed

Gonzalez, J. S., Safren, S. A., Delahanty, L. M., Cagliero, E., Wexler, D. J., Meigs, J. B., & Grant, R. W. (2008). Symptoms of depression prospectively predict poorer self-care in patients with type 2 Diabetes. Diabetic Medicine, 25(9), 1102–1107. https://doi.org/10.1111/j.1464-5491.2008.02535.xCrossRefPubMedPubMedCentral

Grigoriadis, S., & Robinson, G. E. (2007). Gender issues in depression. Annals of Clinical Psychiatry, 19(4), 247–255. https://doi.org/10.1080/10401230701653294CrossRefPubMed

Gupta, S., McColl, M. A., Guilcher, S. J., & Smith, K. (2018). Cost-related nonadherence to prescription medications in Canada: A scoping review. Patient Preference and Adherence, 12, 1699–1715. https://doi.org/10.2147/PPA.S170417CrossRefPubMedPubMedCentral

Heflin, C. M., & Iceland, J. (2009). Poverty, material hardship, and Depression*. Social Science Quarterly, 90(5), 1051–1071. https://doi.org/10.1111/j.1540-6237.2009.00645.xCrossRefPubMedPubMedCentral

Holbrook, A. M., Wang, M., Lee, M., Chen, Z., Garcia, M., Nguyen, L., & Law, M. R. (2021). Cost-related medication nonadherence in Canada: A systematic review of prevalence, predictors, and clinical impact. Systematic Reviews, 10(1), 11. https://doi.org/10.1186/s13643-020-01558-5CrossRefPubMedPubMedCentral

Kang, H., Lobo, J. M., Kim, S., & Sohn, M. W. (2018). Cost-related medication non-adherence among U.S. adults with Diabetes. Diabetes Research and Clinical Practice, 143, 24–33. https://doi.org/10.1016/j.diabres.2018.06.016CrossRefPubMedPubMedCentral

Kennedy, S. H., Lam, R. W., McIntyre, R. S., Tourjman, S. V., Bhat, V., Blier, P., & Group, C. D. W. (2016). Canadian Network for Mood and anxiety treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: Sect. 3. Pharmacological treatments. Canadian Journal of Psychiatry Revue canadienne de psychiatrie, 61(9), 540–560. https://doi.org/10.1177/0706743716659417CrossRefPubMedPubMedCentral

Kroenke, K., Spitzer, R. L., & Williams, J. B. (2001). The PHQ-9: Validity of a brief depression severity measure. Journal of General Internal Medicine, 16(9), 606–613. https://doi.org/10.1046/j.1525-1497.2001.016009606.xCrossRefPubMedPubMedCentral

Law, M. R., Cheng, L., Dhalla, I. A., Heard, D., & Morgan, S. G. (2012). The effect of cost on adherence to prescription medications in Canada. Cmaj, 184(3), 297–302. https://doi.org/10.1503/cmaj.111270CrossRefPubMedPubMedCentral

Law, M. R., Cheng, L., Kolhatkar, A., Goldsmith, L. J., Morgan, S. G., Holbrook, A. M., & Dhalla, I. A. (2018). The consequences of patient charges for prescription Drugs in Canada: A cross-sectional survey. CMAJ Open, 6(1), E63–e70. https://doi.org/10.9778/cmajo.20180008CrossRefPubMedPubMedCentral

Morgan, S. G., & Boothe, K. (2016). Universal prescription drug coverage in Canada: Long-promised yet undelivered. Healthc Manage Forum, 29(6), 247–254. https://doi.org/10.1177/0840470416658907CrossRefPubMedPubMedCentral

National Health Expenditure Trends, 2019. Series G: Expenditure on drugs (2019). Retrieved from Ottawa: https://www.cihi.ca/en/national-health-expenditure-trends

Patel, J. S., Oh, Y., Rand, K. L., Wu, W., Cyders, M. A., Kroenke, K., & Stewart, J. C. (2019). Measurement invariance of the patient health questionnaire-9 (PHQ-9) depression screener in U.S. adults across sex, race/ethnicity, and education level: NHANES 2005–2016. Depression and Anxiety, 36(9), 813–823. https://doi.org/10.1002/da.22940CrossRefPubMedPubMedCentral

Patten, S. B., Williams, J. V., Lavorato, D. H., Wang, J. L., McDonald, K., & Bulloch, A. G. (2015). Descriptive epidemiology of major depressive disorder in Canada in 2012. Canadian Journal of Psychiatry, 60(1), 23–30. https://doi.org/10.1177/070674371506000106CrossRefPubMedPubMedCentral

Piette, J. D., Beard, A., Rosland, A. M., & McHorney, C. A. (2011). Beliefs that influence cost-related medication non-adherence among the haves and have nots with chronic Diseases. Patient Preference and Adherence, 5, 389–396. https://doi.org/10.2147/PPA.S23111CrossRefPubMedPubMedCentral

Public Health Agency of Canada (2014). Mental health promotion: promoting mental health means promoting the best of ourselves. Retrieved from https://www.canada.ca/en/public-health/services/health-promotion/mental-health/mental-health-promotion.html

Ridley, M., Rao, G., Schilbach, F., & Patel, V. (2020). Poverty, depression, and anxiety: Causal evidence and mechanisms. Science, 370(6522), https://doi.org/10.1126/science.aay0214

Statistics Canada (2020). Canadian Community Health Survey — Annual Component (CCHS). Retrieved from https://www23.statcan.gc.ca/imdb/p2SV.pl?Function=getSurvey&Id=1263799

Statistics Canada (2018). Canadian Community Health Survey: Public Use Microdata File, 2015/2016 [Survey data]. Retrieved from: https://hdl.handle.net/11272.1/AB2/VXU9UQ

Tamblyn, R., Eguale, T., Huang, A., Winslade, N., & Doran, P. (2014). The incidence and determinants of primary nonadherence with prescribed medication in primary care: A cohort study. Annals of Internal Medicine, 160(7), 441–450. https://doi.org/10.7326/m13-1705CrossRefPubMed

Tang, K. L., Ghali, W. A., & Manns, B. J. (2014). Addressing cost-related barriers to prescription drug use in Canada. Canadian Medical Association Journal, 186(4), 276–280. https://doi.org/10.1503/cmaj.121637CrossRefPubMedPubMedCentral

Thomas, S., & Wannell, B. (2009). Combining cycles of the Canadian Community Health Survey. Health Reports, 20(1), 53–58.PubMed

Watterson, R. A., Williams, J. V., Lavorato, D. H., & Patten, S. B. (2017). Descriptive epidemiology of generalized anxiety disorder in Canada. Canadian Journal of Psychiatry, 62(1), 24–29. https://doi.org/10.1177/0706743716645304CrossRefPubMed

Wu, Z., Noh, S., Kaspar, V., & Schimmele, C. M. (2003). Race, ethnicity, and depression in Canadian society. Journal of Health and Social Behavior, 44(3), 426–441.CrossRefPubMed

Zhang, J. X., Bhaumik, D., Huang, E. S., & Meltzer, D. O. (2018). Change in insurance status and cost-related Medication non-adherence among older U.S. adults with Diabetes from 2010 to 2014. J Health Med Econ, 4(2), https://doi.org/10.21767/2471-9927.100040

Zhong, H. (2007). Equity in Pharmaceutical utilization in Ontario: A cross-section and over Time Analysis. Canadian Public Policy, 33(4), 487–507. https://doi.org/10.3138/cpp.33.4.487CrossRef

Titel: The Intersectional Impact of Cost-Related Non-Adherence and Depression: A Cross-Sectional Analysis of the Canadian Community Health Survey by Sex, Race, and Indigeneity
verfasst von: Nevena Rebić
Michael R. Law
Lori A. Brotto
Jacquelyn J. Cragg
Mary A. De Vera
Publikationsdatum: 06.11.2023
Verlag: Springer US
Erschienen in: Community Mental Health Journal / Ausgabe 3/2024
Print ISSN: 0010-3853
Elektronische ISSN: 1573-2789
DOI: https://doi.org/10.1007/s10597-023-01202-1

Neu im Fachgebiet Psychiatrie

Wartezeit nicht kürzer, aber Arbeit flexibler

Psychotherapie Medizin aktuell

Fünf Jahren nach der Neugestaltung der Psychotherapie-Richtlinie wurden jetzt die Effekte der vorgenommenen Änderungen ausgewertet. Das Hauptziel der Novellierung war eine kürzere Wartezeit auf Therapieplätze. Dieses Ziel wurde nicht erreicht, es gab jedoch positive Auswirkungen auf andere Bereiche.

Update Psychiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

The Intersectional Impact of Cost-Related Non-Adherence and Depression: A Cross-Sectional Analysis of the Canadian Community Health Survey by Sex, Race, and Indigeneity

Abstract

Neu im Fachgebiet Psychiatrie

Wartezeit nicht kürzer, aber Arbeit flexibler

Chirurginnen und Chirurgen sind stark suizidgefährdet

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

Endlich: Zi zeigt, mit welchen PVS Praxen zufrieden sind

Update Psychiatrie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2024

From Pathways to Partnerships: Building Patient-Centered Clinical Tracks (PCCT) in Outpatient Community Mental Health Settings

The Way I See It: Older Adults with Mental Illness Share Their Views of Community Life Using Photovoice

Correction: African Americans, Caribbean Blacks and Depression: Which Biopsychosocial Factors Should Social Workers Focus On? Results from the National Survey of American Life (NSAL)

Mutual Aid Groups for Loneliness, Psychosocial Disability, and Continuity of Care

Key Issues in the First Year of Transition for a Large Medicaid-Funded Children’s Service

Exception Reporting: A Novel Approach to Tracking of Multiple Behavioral Health Outcomes

Neu im Fachgebiet Psychiatrie

Wartezeit nicht kürzer, aber Arbeit flexibler

Chirurginnen und Chirurgen sind stark suizidgefährdet

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

Endlich: Zi zeigt, mit welchen PVS Praxen zufrieden sind

Update Psychiatrie